Researchers at Stanford Medicine have identified a genetic condition called "GLP-1 resistance" that affects roughly 10% of the population, explaining why popular weight-loss and diabetes drugs like Ozempic and Wegovy fail to work for some patients. The study, led by Anna Gloyn at Stanford and Markus Stoffel at ETH Zurich, found that variants in the PAM gene cause elevated but biologically ineffective levels of the GLP-1 hormone these drugs target.

Clinical trial analysis of 1,119 participants showed striking differences: 25% of non-carriers achieved target blood sugar levels after six months, compared to just 11.5% of those with the p.S539W variant. The findings, published in Genome Medicine, suggest genetic testing could help doctors identify patients unlikely to benefit from GLP-1 drugs and prescribe alternatives sooner.

"Knowing ahead of time who will respond helps patients get on the right drugs faster," said Gloyn, professor of pediatrics and genetics at Stanford Medicine.